Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 10/20 | 0.51 |
| ▸ | SRC | P12931 | 3/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13928692 | 0.98 | WEE1 (0.51) | WEE1SRCMAPK14LCKFGFR1 | |
| SCHEMBL4173564 | 0.89 | MAPK14 (0.64) | WEE1SRCMAPK14LCKFGFR1 | |
| SCHEMBL4183495 | 0.89 | WEE1 (0.52) | WEE1SRCMAPK14LCKFGFR1 | |
| SCHEMBL13928690 | 0.89 | CDK2 (0.46) | FGFR1TNK2FGFR2FGFR4FGFR3 | |
| SCHEMBL4168908 | 0.88 | PAK1 (0.50) | ABL1TNK2 | |
| SCHEMBL4183783 | 0.87 | TNK2 (0.47) | MAPK14LCKTNK2 | |
| SCHEMBL4169005 | 0.87 | PAK1 (0.49) | TNK2 | |
| SCHEMBL4186245 | 0.86 | LCK (0.49) | WEE1SRCMAPK14LCKFGFR1 | |
| SCHEMBL4180916 | 0.86 | TNK2 (0.49) | TNK2 | |
| SCHEMBL4178386 | 0.86 | PAK1 (0.50) | SRCTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | claimed |
| EP-1846403-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082492-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-10 | — | — | WO | claimed |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS PHARMA AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| CN-107667092-B | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | 诺华股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-10441577-B2 | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) | 2019-10-15 | — | — | US | disclosed |
| EP-3274344-B1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | NOVARTIS PHARMA AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | FGFR4, FGFR1, FGFR3 | WEE1 1270/4885SRC 58/4885MAPK14 257/4885 |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | WEE1 940/4885SRC 2869/4885MAPK14 1114/4885 |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | WEE1 1144/4885SRC 53/4885MAPK14 219/4885 |
| US-10441577-B2 | Medicament for treatment of liver cancer | PYGL, PFKL, GLS2 | WEE1 1514/4885SRC 43/4885MAPK14 523/4885 |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | WEE1 1144/4885SRC 53/4885MAPK14 219/4885 |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | IL1B, TPMT, IL1R1 | WEE1 2618/4885SRC 3064/4885MAPK14 1323/4885 |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | PYGL, PFKL, GLS2 | WEE1 1514/4885SRC 43/4885MAPK14 523/4885 |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | WEE1 1144/4885SRC 53/4885MAPK14 219/4885 |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, CD274, IL15 | WEE1 824/4885SRC 2540/4885MAPK14 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.